BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 16, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2004

View Archived Issues

Cardiac chymase: a novel target in post-MI treatment

Read More

Action of NS-8 on micturation reflex investigated in rat model

Read More

Effective local bone formation and fracture healing by CP-533536

Read More

Novel KSP inhibitors identified by Merck researchers

Read More

Roche scientists present new MAO-B inhibitors for AD and senile dementia

Read More

New antipsychotic agents with 5-HT and dopamine receptor activity

Read More

Two series of morpholine-based CCR3 antagonists under study at GSK

Read More

New protein kinase inhibitors and their use in cancer therapy reported by Cytopia

Read More

A phase III clinical trial confirms the benefits of Prialt in patients with severe chronic pain

Read More

Sertraline helps depression and quality of life after hospitalization for acute coronary syndrome

Read More

PPD amends dapoxetine license

Read More

Akzo Nobel to transfer Arixtra to Sanofi-Synthelabo

Read More

Targeted Genetics extends AIDS vaccine partnership

Read More

Ranbaxy generic minocycline hydrochloride approved for marketing

Read More

Clearance for pivotal Canadian phase IIb/III trial for Tectin

Read More

Pfizer advances Atrigel product into further clinical testing

Read More

Oraqix receives FDA approval

Read More

Nutrition 21 seeks approval of chromium picolinate health benefit claims

Read More

Approvable letter for Fortical

Read More

Phase I/II trial of MTC-MMC in NSCLC cleared to begin

Read More

Alpharma launches generic equivalent of Lotrisone

Read More

Prefilled Pegasys syringes approved by FDA

Read More

Patient testing completed in phase III Cellegesic trial

Read More

LymphoStat-B enters phase II evaluation for active rheumatoid arthritis

Read More

Memantine reported effective and safe in patients with mild to moderate Alzheimer's disease

Read More

End of patient enrollment announced for two clinical trials with Velac(R) Gel

Read More

Favrille completes enrollment in a phase II clinical trial of FavId for fNHL

Read More

Ambrisentan enters phase III clinical development

Read More

Approval granted to an expanded use of Eloxatin for metastatic colorectal cancer in Europe

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 13, 2026.
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • Skin irritation on hands

    HX-16108 holds promise for treating inflammatory skin diseases

    BioWorld Science
    Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing